Literature DB >> 3594389

Urinary bladder cancer. Selecting initial therapy.

G H Friedell.   

Abstract

Selection of optimal primary therapy for bladder cancer patients requires a multidisciplinary approach based on an evaluation of the location, extent and, if possible, the virulence of the tumor(s), and the host response. Currently, cystoscopic observation and morphologic assessment of cellular and tissue specimens are the main sources of information. The urologist and pathologist are chiefly responsible for collecting this information, but other laboratory approaches also are being developed. The urologist must prepare a "seen at cystoscopy" diagram of the bladder mucosal surface and indicate in both the diagram and the cystoscopy report the number, location and appearance of tumors and other abnormalities. The cytopathologist must be as precise as possible in defining abnormalities in cellular preparations, and the histopathologist must not only indicate the microscopic diagnosis but the presence or absence of muscle in each biopsy specimen.

Entities:  

Mesh:

Year:  1987        PMID: 3594389     DOI: 10.1002/1097-0142(19870801)60:3+<496::aid-cncr2820601511>3.0.co;2-h

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  2 in total

1.  The value of tumour spread, grading and growth pattern as morphological predictive parameters in bladder carcinoma. A critical revision of the 1987 TNM classification.

Authors:  J C Angulo; J I Lopez; N Flores; J D Toledo
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

2.  Methotrexate, vinblastine, epidoxorubicin and cisplatin (M-VEC) in patients with locally advanced transitional bladder cancer.

Authors:  A Frassoldati; M Federico; F Barbieri; M Brausi; C Pollastri; G Berri; G Castagnetti; P P Palladini; V Silingardi
Journal:  Med Oncol Tumor Pharmacother       Date:  1991
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.